Navigation Links
Glenveigh Medical and Monica Healthcare Announce Distribution Agreement for Groundbreaking FDA Cleared Wireless Fetal Monitoring System
Date:2/28/2011

CHATTANOOGA, Tenn., Feb. 28, 2011 /PRNewswire/ -- Glenveigh Medical, LLC and Monica Healthcare Limited today announced an agreement for exclusive distribution rights in the United States as well as US territories and military bases for Monica Healthcare's AN24 wireless fetal monitoring system. The system recently received FDA regulatory clearance for use during labor and delivery. Marketed under the trade name Beacon by Monica™, the wireless fetal monitoring system will be available in U.S. hospitals exclusively through Glenveigh and promoted by Glenveigh's sales and distribution partner Norgenix Pharmaceuticals, LLC. Glenveigh is a life science and technology company focused on advancing the practice of obstetrics worldwide. United Kingdom-based Monica Healthcare develops wireless technologies for use in obstetrics.

"We are pleased to announce our partnership with Monica," stated C. David Adair, M.D., Founder, Chairman, and Chief Scientific Officer of Glenveigh Medical. "The Beacon by Monica™ is a break-though wireless device that monitors the fetal heart rate and uterine activity while allowing patients to ambulate without the usual nurse intervention."

Rick Proctor, President and CEO of Glenveigh Medical, added, "The Monica AN24 technology was validated in a rigorous clinical study that was reviewed by the FDA as part of the 510(k) clearance process."

The Beacon by Monica™ is simple to use, beltless, requires no wires to connect to a display or printer, and is designed to provide high levels of patient satisfaction. There is no need for the constant re-positioning of transducers which is required with current technology. Clinical trials also demonstrated that the device performs well in obese women where use of conventional technology can be challenging.

"This technology has already generated a tremendous amount of excitement and interest," stated Jeff Bradford, VP of Marketing for Glenveigh. "We are already receiving inquiries about product availability as clinicians are eager to try the device because it monitors the fetal ECG waveform."

Carl Barrett, Chief Executive Officer of Monica Healthcare is very optimistic about the potential for the Beacon by Monica™ in the United States. Barrett explained, "With the reputation of Glenveigh with clinicians, combined with Norgenix's nationwide sales force, we expect to penetrate the market rapidly."

For order inquires, call Norgenix at 877-320-5174 or visit www.norgenixpharma.com.

GLENVEIGH MEDICAL | www.glenveigh.com

MONICA HEALTHCARE LIMITED  |  www.monicahealthcare.com  

NORGENIX  |  www.norgenixpharma.com MEDIA CONTACT: Sims Hammond, 864.580.2350, Sims@LaunchSomething.com
'/>"/>

SOURCE Glenveigh Medical, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... VALLEY COTTAGE, New York , January 23, 2017 ... Projected to Witness Sluggish Growth ... world are derived from formulating Active Pharmaceutical Ingredients (API), ... isopropanol, propanol and propylene glycol. Production of ... Asia-Pacific excluding Japan ...
(Date:1/23/2017)... , Jan. 23, 2017 Endo International plc ... Commission (FTC) today filed a joint motion in the ... California seeking the entry of a ... resolves all disputes between the FTC and Endo relating ... connection with its Opana® ER and Lidoderm® products.  It ...
(Date:1/23/2017)... DUBLIN , Jan. 23, 2017 Research ... Products Market - Forecast to 2021" report to their offering. ... The interventional ... 2021 from USD 6.35 Billion in 2016, at a CAGR of ... region. The major factors driving the growth of this ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... ... “Mysteries Revealed On Speaking In Tongues”: an engaging and dynamic study ... “Mysteries Revealed On Speaking In Tongues” is the creation of published author, Tina Jackson, ... in Michigan. , “We need to partner with Jesus and be the voice ...
(Date:1/24/2017)... ... January 24, 2017 , ... HealthCarePoint ... survivors, today announced formation of its first global advisory board to help ... , Like HCP founders, the global advisory board is composed of key ...
(Date:1/24/2017)... ... January 23, 2017 , ... CLICKco LLC, a company known ... its CLICK® Coffee Protein Drink is now available for purchase on RevNutrition.com, a ... popular among health-conscious consumers who love coffee but are looking to add more ...
(Date:1/24/2017)... ... January 23, 2017 , ... OSF Ventures, ... the world’s largest start-up platform headquartered in Silicon Valley that connects startups to ... Ventures recently signed a three-year agreement to be a corporate sponsor of Plug ...
(Date:1/24/2017)... ... 2017 , ... The January 2017 issue of the Journal of Counseling & ... behavioral healthcare (OBH) – also known as wilderness therapy – helped a group of ... sense of purpose both during and after treatment. , The study was published ...
Breaking Medicine News(10 mins):